Inactivated CD8+ T-cells for the treatment of HIV infection
AssigneesYeda Research and Development Co. Ltd., Hadasit Medical Research Services and Dev. Ltd
InventorsRivka Abulafia-Lapid, Henri Atlan, Irun R. Cohen
Life of this patent
Estimating the term…
Abstract
A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.
Claims4
A method of preparing a population of autologous T-cells enriched with inactivated CD8+ cells that are reactive to CD4+ cells, said method consisting of the steps of:
- a) Obtaining peripheral mononuclear blood cells (PMBC) from said patient;
- b) Culturing said autologous cells in the presence of a nonspecific stimulating factor;
- c) Expanding said autologous cells in the presence of IL-2, wherein said IL-2 is provided at 5-20 U/ml;
- d) Culturing said expanded autologous cells in the presence of irradiated CD4-pulsed antigen presenting cells (APCs);
- e) Inactivating said autologous cells in the presence of an inactivating factor;
- f) Washing said autologous cells and resuspending the same in injection-grade saline solution;
- and
- g) Optionally freezing aliquots of between 106-108 cells in liquid nitrogen.
Dependencies are inferred from the claim text.